LOGIN  |  REGISTER
Viking Therapeutics
Assertio

Shoulder Innovations to Report Second Quarter 2025 Financial Results on September 9, 2025

August 28, 2025 | Last Trade: US$15.73 0.73 4.87
  • Company to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on the Same Day

GRAND RAPIDS, Mich., Aug. 28, 2025 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it will release financial results for the second quarter of 2025 before market open on Tuesday, September 9, 2025.

On the same day, members of management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference. The fireside chat will take place at 8:30 a.m. ET / 5:30 a.m. PT on September 9, 2025.

A live and archived version of the fireside chat will be available on the "Investor Relations" section of the Shoulder Innovations website at https://ir.shoulderinnovations.com/.

About Shoulder Innovations

Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations' ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations' ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.

Contact
Brian Johnston or Sam Bentzinger 
Gilmartin Group LLC 
This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Last Trade: US$15.73
Daily Change: 0.73 4.87
Daily Volume: 139,064
Market Cap: US$498.010M

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page